• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
GAO Rui,GAO Xinghua.Research progress of dsRNA in anti-tumor immunity[J].Journal Of Pharmaceutical Research,2025,44(5):491-496[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2071times   Download 706次 QR Code for this article
Scan with your phone!
dsRNA在激活抗肿瘤免疫中的研究进展
高锐1,高兴华2
Font:Larger+|Default|Smaller-
(1.中国药科大学多靶标天然药物全国重点实验室,江苏 南京 211198;2.中国药科大学基础医学与临床药学学院,江苏 南京 211198)
摘要:
双链RNA(double-stranded RNA,dsRNA)是一种具有重要生物学功能的核酸分子,广泛存在于病毒基因组和宿主免疫反应过程中。在近年来的研究中,dsRNA作为免疫反应的强效激活因子,能够通过激活模式识别受体,从而触发一系列信号转导过程,诱导I型干扰素和炎症细胞因子的表达,最终有效激活机体免疫应答,成为癌症免疫治疗中的一个重要研究方向。本文系统综述了dsRNA在抗肿瘤免疫中的最新研究进展,重点探讨了其通过dsRNA感应通路的激活、病毒拟态机制以及参与肿瘤微环境重塑等多种机制促进抗肿瘤免疫的作用。此外,本文还阐述了dsRNA在癌症疫苗开发、免疫检查点抑制剂联用以及RNA干扰疗法等前沿治疗策略中的应用潜力,旨在为dsRNA在癌症免疫治疗中的进一步研究和应用提供更为明确的方向与思路。
关键词:  dsRNA  抗肿瘤免疫  病毒拟态反应
DOI:10.13506/j.cnki.jpr.2025.05.012
基金项目:国家自然科学基金项目(No.82273329、32470989)
Publication Date:May 25, 2025
Research progress of dsRNA in anti-tumor immunity
GAO Rui1,GAO Xinghua2
(1. State Key Laboratory of Nature Medicines,China Pharmaceutical University, Nanjing 211198,China;2.School of Basic Medicine and Clinical Pharmacy,China Pharmaceutical University,Nanjing 211198,China)
Abstract:
Double-stranded RNA (dsRNA) is a nucleic acid molecule with significant biological functions, widely present in viral genomes and host immune response processes. In recent studies, dsRNA has been identified as a potent activator of immune responses, capable of triggering a series of signal transduction pathways by engaging pattern recognition receptors (PRRs). This activation leads to the induction of type I interferons (IFNs) and pro-inflammatory cytokines, ultimately eliciting robust immune responses. Consequently, dsRNA has emerged as a critical focus in cancer immunotherapy research. This review systematically summarized the latest advancements in the role of dsRNA in antitumor immunity, with a particular emphasis on its mechanisms of action, including the activation of dsRNA-sensing pathways,viral mimicry, and remodeling of the tumor microenvironment. Furthermore, the review explored the potential applications of dsRNA in cutting-edge therapeutic strategies, such as cancer vaccine development, combination therapy with immune checkpoint inhibitors, and RNA interference (RNAi)-based therapies. By synthesizing a comprehensive analysis of these mechanisms and applications, this review aims to offer clearer research directions and insights for the further utilization of dsRNA in cancer immunotherapy.
Key words:  Double-stranded RNA  Antitumor immunity  Viral mimicry response
Today's Visits:511    Total Visits:2383242
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.